Associated Papers
Genetic and molecular architecture of familial hypercholesterolemia.
Abifadel M et al.
Journal of Internal Medicine, 2023
Screening for Familial Hypercholesterolemia in Small Towns: Experience from 11 Brazilian Towns in the Hipercolbrasil Program.
Jannes CE et al.
Arquivos Brasileiros De Cardiologia, 2022
Taking One Step Back in Familial Hypercholesterolemia: STAP1 Does Not Alter Plasma LDL (Low-Density Lipoprotein) Cholesterol in Mice and Humans.
Loaiza N et al.
Arteriosclerosis, Thrombosis, and Vascular Biology, 2020
Six years' experience with LipidSeq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias.
Dron JS et al.
Bmc Medical Genomics, 2020
32041611 (PubMed )
Supplement: 12920_2020_669_MOESM1_ESM.xlsx › Supp_Table_4
Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia.
Lamiquiz-Moneo I et al.
Atherosclerosis, 2020
PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis.
Guo Q et al.
Frontiers in Genetics, 2020
Genes Potentially Associated with Familial Hypercholesterolemia.
Mikhailova S et al.
Biomolecules, 2019
Evaluation of the role of STAP1 in Familial Hypercholesterolemia.
Danyel M et al.
Scientific Reports, 2019
A rare STAP1 mutation incompletely associated with familial hypercholesterolemia.
Blanco-Vaca F et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2018
Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia.
Fouchier SW et al.
Circulation Research, 2014
25035151 (PubMed )
Supplement: 304660r2_online.pdf
Select a paper to view details